Breaking News

CEL-SCI Readies Multikine Facility for Commercial Scale Production

Preparation for biologics license application for regulatory approval submissions.

CEL-SCI Corporation reported that its Multikine (Leukocyte Interleukin, Injection) cGMP state-of-the-art dedicated manufacturing facility commissioning is complete, representing a significant milestone toward a planned Biologics License Application (BLA) with several regulatory agencies for approval of Multikine in the treatment of head and neck cancer. Originally constructed and validated to supply Multikine for the world’s largest global pivotal Phase 3 trial in locally advanced squamous ce...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters